Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR4 | O95977 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 3/20 | 0.35 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 5/20 | 0.32 |
| ▸ | RAB9A | P51151 | 5/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.32 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.32 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.32 |
| ▸ | RELA | Q04206 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27787626 | 0.85 | S1PR4 (0.40) | S1PR4SLC2A1LMNAHTTKMT2A | |
| SCHEMBL4050836 | 0.85 | NPC1 (0.35) | S1PR4MAPTNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL7806544 | 0.84 | CCR1 (0.44) | S1PR4MAPTSLC2A1NPC1RAB9A | |
| SCHEMBL7245334 | 0.74 | KDM4E (0.55) | MAPTNPC1RAB9ASMN1; SMN2KDM4E | |
| SCHEMBL627005 | 0.74 | S1PR4 (0.46) | S1PR4MAPTNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL7245330 | 0.74 | KDM4E (0.55) | MAPTNPC1RAB9ASMN1; SMN2KDM4E | |
| SCHEMBL4052149 | 0.73 | CYP1A2 (0.48) | MAPTKDM4ELMNA | |
| SCHEMBL11517006 | 0.73 | S1PR4 (0.45) | S1PR4MAPTSLC2A1NPC1RAB9A | |
| SCHEMBL6819092 | 0.71 | CCR1 (0.48) | S1PR4MAPTNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL7801389 | 0.69 | CCR1 (0.42) | S1PR4MAPTKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101591291-A | The synthetic method of 2-ethenyl quinoline compound | INST MATERIA MEDICA CAMS (CN) | 2009-12-02 | — | — | CN | claimed |
| CN-101591291-A | The synthetic method of 2-ethenyl quinoline compound | INST MATERIA MEDICA CAMS (CN) | 2009-12-02 | — | — | CN | disclosed |
| US-7557212-B2 | Tricyclic derivatives as LTD4 antagonists | LABORATORIOS ALMIRALL, S.A. (ES) | 2009-07-07 | — | — | US | disclosed |
| EP-1560834-B1 | NEW TRICYCLIC DERIVATIVES AS LTD4 ANTAGONISTS | ALMIRALL LAB (ES) | 2008-06-25 | — | — | EP | disclosed |
| CN-100379742-C | novel tricyclic derivatives as LTD4 antagonists | ALMIRALL PRODESFARMA SA (ES) | 2008-04-09 | — | — | CN | disclosed |
| US-7309718-B2 | Dibenzocycloheptene compound | UBE INDUSTRIES, LTD. (JP) | 2007-12-18 | — | — | US | disclosed |
| US-20060116363-A1 | Tricyclic derivatives as ltd4 antagonists | LABORATORIOS ALMIRALL, S.A. (ES) | 2006-06-01 | — | — | US | disclosed |
| CN-1735618-A | New tricyclic derivatives as LTD4 antagonists | ALMIRALL PRODESFARMA SA (ES) | 2006-02-15 | — | — | CN | disclosed |
| CN-1240684-C | Dibenzocycloheptene compound | UBE INDUSTRIES (JP) | 2006-02-08 | — | — | CN | disclosed |
| EP-1560834-A1 | NEW TRICYCLIC DERIVATIVES AS LTD4 ANTAGONISTS | Almirall Prodesfarma, S.A. (ES) | 2005-08-10 | — | — | EP | disclosed |
| CN-1531528-A | Dibenzocycloheptene compound | ��˲���ʽ���� | 2004-09-22 | — | — | CN | disclosed |
| US-20040180884-A1 | Dibenzocycloheptene compound | UBE INDUSTRIES, LTD. (JP) | 2004-09-16 | — | — | US | disclosed |
| WO-2004043966-A1 | NEW TRICYCLIC DERIVATIVES AS LTD4 ANTAGONISTS | ALMIRALL PRODESFARMA S.A. (ES) | 2004-05-27 | — | — | WO | disclosed |
| EP-1408033-A1 | DIBENZOCYCLOHEPTENE COMPOUND | Ube Industries, Ltd. (JP) | 2004-04-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060116363-A1 | Tricyclic derivatives as ltd4 antagonists | LTA4H, LTC4S, LTB4R2 | S1PR4 102/4885MAPT 4493/4885SLC2A1 4782/4885 |
| US-20040180884-A1 | Dibenzocycloheptene compound | LTB4R2, LTA4H, LTC4S | S1PR4 981/4885MAPT 4409/4885SLC2A1 4117/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.